Newsletter Tool

PM Tracker

Editor's Note: Fierce PM Tracker will not publish Monday, Sept. 2, for the Labor Day holiday. We’ll be back in your inbox Tuesday, Sept. 3.

Today’s Big News

Aug 30, 2024

Novo rekindles heart failure hopes for semaglutide with new pooled analysis

Allist pays Jacobio $21M for KRAS drug combo, landing leading role in Chinese cancer race

FDA approves re-expandable stent that can grow in size along with young children

Takeda taps longtime FleishmanHillard alum to head up global corporate brand and content

Alnylam's Amvuttra turns in 'grand slam' showing in ATTR-CM, but leaves a window open for rivals

Chutes & Ladders—Cell-focused Sana scoops first CSO

Eli Lilly partner Hutchmed scraps China stomach cancer filing as approval seems unlikely

Featured

Novo rekindles heart failure hopes for semaglutide with new pooled analysis

By Fraiser Kansteiner

Novo’s semaglutide cut the risk of combined cardiovascular death or worsening heart failure events by 31%, based on an incident rate of 5.4% in semaglutide patients versus 7.5% in those on placebo, the company said Friday. Semaglutide also led to a 41% lower risk of worsening HF, according to a pooled analysis of four Novo Nordisk trials.

Allist pays Jacobio $21M for KRAS drug combo, landing leading role in Chinese cancer race

By Nick Paul Taylor

Shanghai Allist Pharmaceuticals has bought itself a starring role in China’s KRAS market, paying Jacobio Pharma 150 million Chinese yuan ($21 million) for rights to a near-approval inhibitor of the oncogene and a potentially complementary molecule.

FDA approves re-expandable stent that can grow in size along with young children

By Conor Hale

Renata Medical’s Minima stent is designed for infants and young children, including neonates born with congenital heart defects.

Takeda taps longtime FleishmanHillard alum to head up global corporate brand and content

By Andrea Park

A new appointee with more than two decades of comms experience will soon take the reins of Takeda’s worldwide brand strategy.

Alnylam's Amvuttra turns in 'grand slam' showing in ATTR-CM, but leaves a window open for rivals

By Kevin Dunleavy

At the European Society of Cardiology conference in London, Alnylam presented positive data from the phase 3 HELIOS-B trial which assessed RNA silencer Amvuttra (vutrisiran) as a treatment for transthyretin amyloid cardiomyopathy (ATTR-CM).

Chutes & Ladders—Cell-focused Sana scoops first CSO

By Darren Incorvaia,Zoey Becker,Gabrielle Masson

Cell engineering biotech Sana Biotechnology is bringing Dhaval Patel, M.D., Ph.D., on board as its first ever chief scientific officer.

Eli Lilly partner Hutchmed scraps China stomach cancer filing as approval seems unlikely

By Angus Liu

Hutchmed, the original developer of Takeda’s Fruzaqla, has decided not to pursue an approval for the VEGFR inhibitor in stomach cancer in its home country for now thanks to doubts around patients’ overall survival.

ReNeuron joins exodus from AIM exchange after missing fundraising goal

By Nick Paul Taylor

ReNeuron has joined the long list of biotechs to leave London’s AIM stock market. The stem cell biotech is letting go of its listing after money troubles persuaded it to free itself from the costs and regulatory obligations of the exchange.

Catalent reports upbeat Q4 results as it awaits FTC review of $16.5B sale to Novo

By Joseph Keenan

CDMO giant Catalent, which continues to wait on a twice-extended review by the Federal Trade Commission of its sale to Novo Holdings for $16.5 billion, reported upbeat fourth-quarter earnings.

Fierce podcasts

Don’t miss an episode

Driving flu vaccine uptake in the post pandemic era

In this week's episode of "The Top Line," we look at factors driving the continuing decline of flu vaccination rates in the U.S. and beyond.

The TROP2 race for supremacy

The future of health AI: Local governance, national standards

Resources

Whitepaper

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.

Launching a Product in Europe: Understanding Supply Chain Cost Drivers

This paper explores the costs of setting up a supply chain in Europe for a new biopharma therapy. It outlines key cost drivers & the various levers decision makers can use to affect those costs.